Literature DB >> 29179977

Altered O-glycosylation is associated with inherent radioresistance and malignancy of human laryngeal carcinoma.

Xiaoxia Dong1, Zhiguo Luo2, Yingying Wang3, Lu Meng3, Qiwen Duan2, Li Qiu2, Feng Peng2, Li Shen4.   

Abstract

Radioresistance (inherent or acquired) remains a major obstacle affecting the clinical outcome of radiotherapy for laryngeal carcinoma. Results from our laboratory and other groups suggest that aberrant glycosylation contributes to cancer acquired radioresistance. However, the role of glycosylation in inherent radioresistance of laryngeal carcinoma has not been fully uncovered. In this study, we investigated the glycan profiling of the inherent radioresistant (Hep-2max) and radiosensitive (Hep-2min) cell lines using lectin microarray analysis. The results revealed that the radioresistant cell line Hep-2max presented higher core 1-type O-glycans than the sensitive one. Further analysis of the O-glycan regulation by benzyl-α-GalNAc application in Hep-2max cells showed partial inhibition of the O-glycan biosynthesis and increased radiosensitivity. In addition, core 1 β1, 3-galactosyltransferase (C1GALT1) overexpression in Hep-2min cells enhanced cell migration, invasion, and radioresistance. Conversely, knockdown of C1GALT1 in Hep-2max cells was able to suppress these malignant phenotypes. Moreover, mechanistic investigations showed that C1GALT1 modified the O-glycans on integrin β1 and regulated its activity. The glycosylation-mediated radioresistance was further inhibited by anti-integrin β1 blocking antibody. Importantly, we also observed that core 1-type O-glycans expression was correlated with advanced tumor stage, metastasis, and poor survival of laryngeal carcinoma patients. These findings suggest that altered O-glycosylation can lead to the inherent radioresistance and progression, and therefore may be important for enhancing the efficacy of radiotherapy in laryngeal carcinoma.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inherent radioresistance; Laryngeal carcinoma; Malignancy; O-glycosylation

Mesh:

Substances:

Year:  2017        PMID: 29179977     DOI: 10.1016/j.yexcr.2017.11.031

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  Cosmc overexpression enhances malignancies in human colon cancer.

Authors:  Tianbo Gao; Tan Du; Xin Hu; Xichen Dong; Lina Li; Yakun Wang; Jian Liu; Lijie Liu; Tao Gu; Tao Wen
Journal:  J Cell Mol Med       Date:  2019-10-21       Impact factor: 5.310

Review 2.  Update on the role of C1GALT1 in cancer.

Authors:  Tong Xia; Ting Xiang; Hailong Xie
Journal:  Oncol Lett       Date:  2022-01-27       Impact factor: 2.967

3.  Glycosylated modification of MUC1 maybe a new target to promote drug sensitivity and efficacy for breast cancer chemotherapy.

Authors:  Xiaomin Xi; Jiting Wang; Yue Qin; Weidong Huang; Yilin You; Jicheng Zhan
Journal:  Cell Death Dis       Date:  2022-08-16       Impact factor: 9.685

4.  C1GALT1, Negatively Regulated by miR-181d-5p, Promotes Tumor Progression via Upregulating RAC1 in Lung Adenocarcinoma.

Authors:  Xiaoxia Dong; Yongyu Liu; Xinzhou Deng; Jun Shao; Shuangyue Tian; Shuang Chen; Rongxin Huang; Ziao Lin; Chunli Chen; Li Shen
Journal:  Front Cell Dev Biol       Date:  2021-07-07

Review 5.  C1GALT1 in health and disease.

Authors:  Xiaojie Sun; Mengru Zhan; Xun Sun; Wanqi Liu; Xiangwei Meng
Journal:  Oncol Lett       Date:  2021-06-06       Impact factor: 2.967

6.  Knockdown of C1GalT1 inhibits radioresistance of human esophageal cancer cells through modifying β1-integrin glycosylation.

Authors:  Chuanyi Zhang; Xinzhou Deng; Li Qiu; Feng Peng; Shanshan Geng; Li Shen; Zhiguo Luo
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

Review 7.  Expression and Impact of C1GalT1 in Cancer Development and Progression.

Authors:  Yangu Wan; Lu-Gang Yu
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.